Newsmeme!
Discover News you didn't know existed
La Jolla
News
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients ...
Published December 2, 2008, 5:30 am, PR Newswire via Yahoo! Finance
TorreyPines Therapeutics, Inc. today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome.
Tags
No tags found at this time. Be the first to tag this news item, learn more.
Imagery
Related La Jolla Stories
From Various News Sources
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary ... - Phramalive.com
LA JOLLA, Calif., December 02, 2008 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with ...
TorreyPines Therapeutics Dry Mouth Treatment Meets Primary Endpoint In ... - RTT News
(RTTNews) - TorreyPines Therapeutics, Inc. (TPTX: News ) Tuesday said tbat a phase II trial evaluating three doses of Muscarinic agonist NGX267 as a treatment for xerostomia or dry mouth in patients with Sjogren's syndrome has met its primary end ...
Related Social Bookmarks
None found at this time.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |